Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 13/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 13/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168917 | 0.91 | CYP2D6 (0.37) | CYP2D6KCNH2HRH3UBE2MDCUN1D1 | |
| SCHEMBL21776124 | 0.85 | UBE2M (0.34) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL26530253 | 0.82 | HRH3 (0.39) | CYP2D6KCNH2HRH3KMT2APAX8 | |
| SCHEMBL19040733 | 0.79 | UBE2M (0.31) | UBE2MDCUN1D1 | |
| SCHEMBL12384749 | 0.78 | CYP2D6 (0.42) | CYP2D6KCNH2HRH3 | |
| SCHEMBL25447572 | 0.78 | SIGMAR1 (0.46) | UBE2MDCUN1D1KMT2AOPRM1OPRL1 | |
| SCHEMBL25090277 | 0.78 | OPRM1 (0.36) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL23168732 | 0.77 | HRH3 (0.38) | CYP2D6KCNH2HRH3 | |
| SCHEMBL11573468 | 0.76 | — | — | |
| SCHEMBL19630484 | 0.76 | KDM4E (0.38) | UBE2MDCUN1D1KMT2AOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CYP2D6 4817/4885KCNH2 3642/4885HRH3 2787/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CYP2D6 4817/4885KCNH2 3642/4885HRH3 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.